A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
A phase 1/2 trial of Temozolomide in melanoma and prostate cancer, run by Sapience Therapeutics, active and no longer recruiting.
Overview
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04478279 by Sapience Therapeutics, with 125 participants enrolled, started 2020-07-01 and due to reach its primary completion in 2026-12. Interventions recorded: ST101, Temozolomide, Radiation. Conditions listed: Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Shares Brain and spinal cord tumours (all types), Temozolomide.
- TrialA Phase II Trial of LM103 in Advanced Melanoma
Shares Temozolomide, Melanoma.
- TrialA Study of GC101 TIL in Advanced Melanoma
Shares Temozolomide, Melanoma.
- InstitutionRobert H. Lurie Comprehensive Cancer Center of Northwestern University
Shares Temozolomide, Prostate cancer.
- TreatmentDacarbazine
Shares Temozolomide, Melanoma.
- TreatmentDabrafenib
- TargetMEK1/2
- PathwayBase excision repair, PARP & alkylation damage
Shares Temozolomide, Prostate cancer.